Exelixis Stock Soars As Analysts Applaud Raised 2025 Guidance, Q1 Earnings Beat

benzinga.com/general/biotech/25/05/45418036/exelixis-stock-soars-as-analysts-applaud-raised-2025-guidance-q1-earnings-beat

Exelixis Inc. (NASDAQ:EXEL) on Tuesday reported its first quarter of 2025 adjusted earnings of 62 cents per share, compared to 17 cents a year ago, beating the consensus of 36 cents.
The cancer-focused company reported quarterly sales of $555.45 million, beating the consensus of $498.18…

This story appeared on benzinga.com, 2025-05-14 18:55:10.
The Entire Business World on a Single Page. Free to Use →